29
35.
Politis, M.
et al. Parkinson’s disease symptoms: the patient's perspective.
Mov. Disord. 25, 1646–51 (2010).
36.
Visser, M.
et al. A comprehensive model of health-related quality of life in Parkinson’s disease.
J. Neurol. 255, 1580–7 (2008).
37.
Rahman, S., Griffin, H. J., Quinn, N. P. & Jahanshahi, M. Quality of life in Parkinson’s disease: the relative importance of the symptoms.
Mov Disord
23, 1428–34 (2008).
38.
Goetz, C. G.
et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.
Mov. Disord.
19, 1020–8 (2004).
39.
Evans, J. R.
et al. The natural history of treated Parkinson’s disease in an incident, community based cohort.
J. Neurol. Neurosurg. Psychiatry 82,
1112–8 (2011).
40.
Sato, K. et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov. Disord. 21, 1384–95 (2006).
41.
Fall, P. A., Saleh, A., Fredrickson, M., Olsson, J. E. & Granérus, A. K. Survival time, mortality, and cause of death in elderly patients with
Parkinson’s disease: A 9-year follow-up. Mov. Disord. 18, 1312–1316 (2003).
42.
Fernandez, H. H. & Lapane, K. L. Predictors of mortality among nursing home residents with a diagnosis of Parkinson’s disease.
Med. Sci. Monit. 8,
CR241–R246 (2002).
43.
Hely, M. a, Reid, W. G. J., Adena, M. a, Halliday, G. M. & Morris, J. G. L. The Sydney multicenter study of Parkinson’s disease: the inevitability of
dementia at 20 years.
Mov. Disord. 23, 837–44 (2008).
44.
Schrag, A. & Schott, J. M. Epidemiological ,
clinical , and genetic characteristics of early-onset parkinsonism.
5, (2006).
45.
Abendroth, M., Lutz, B. J. & Young, M. E. Family caregivers’ decision process to institutionalize persons with Parkinson's disease: a grounded theory
study. Int. J. Nurs. Stud. 49, 445–54 (2012).
46.
Goetz, C. G. & Stebbins, G. T. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43, 2227–2229 (1993).
47.
Hely, M. a et al. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatry 67,
300–307 (1999).
48.
Hely, M. a., Morris, J. G. L., Reid, W. G. J. & Trafficante, R. Sydney Multicenter Study of Parkinson’s disease: Non-L-dopa-responsive problems
dominate at 15 years. Mov. Disord. 20, 190–199 (2005).
49.
Willis, a W., Schootman, M. & Evanoff, B. a. Neurologist care in Parkinson disease. 851–858 (2011). doi:10.1212/WNL.0b013e31822c9123
50.
Steendam-oldekamp, T. E., Rutgers, a W. F. W. & Buskens, E. Kortdurende gespecialiseerde revalidatie van Parkinson-patiënten stelt
verpleeghuisopname uit. 156, 0–5 (2012).
51.
Keus, S.
et al. European Physiotherapy Guideline for Parkinson’s Disease Developed with twenty European professional associations.
52.
van der Marck, M. a
et al. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial.
Mov. Disord. 28, 605–11
(2013).
53.
Morris, M. Movement disorders in people with Parkinson disease: a model for physical therapy. Phys. Ther. 80, 578–597 (2000).
54.
Meek, C. E. Improving the clinical effectiveness of physiotherapy in Parkinson¿s disease. PQDT - UK Irel. (2012). at
Dostları ilə paylaş: